Effects of melanocortin adrenocorticotropic anti-opioid peptide tetracosactide on survival in high-risk patients undergoing cardiac surgery
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Tetracosactide (Primary)
- Indications Inflammation
- Focus Therapeutic Use
- 20 Oct 2015 New trial record
- 02 Sep 2015 Primary endpoint (Survival at 30 days) has been met, according to abstract presented as ESC Congress 2015.
- 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.